NSE - Delayed Quote INR

Procter & Gamble Health Limited (PGHL.NS)

Compare
5,301.10
+44.55
+(0.85%)
At close: 3:30:01 PM GMT+5:30
Loading Chart for PGHL.NS
  • Previous Close 5,256.55
  • Open 5,260.00
  • Bid --
  • Ask --
  • Day's Range 5,232.55 - 5,330.00
  • 52 Week Range 4,636.55 - 5,850.00
  • Volume 3,788
  • Avg. Volume 8,992
  • Market Cap (intraday) 88.042B
  • Beta (5Y Monthly) 0.46
  • PE Ratio (TTM) 37.21
  • EPS (TTM) 142.45
  • Earnings Date May 29, 2025
  • Forward Dividend & Yield 160.00 (3.04%)
  • Ex-Dividend Date Feb 21, 2025
  • 1y Target Est --

Procter & Gamble Health Limited engages in the manufacture and marketing of pharmaceuticals and chemical products in India and internationally. The company provides over-the-counter products, vitamins, minerals, and supplements. It offers its products under the Polybion, Cosome, Evion, Neurobion, Nasivion, Livogen, and Seven Seas brands. The company was formerly known as Merck Limited and changed its name to Procter & Gamble Health Limited in May 2019. The company was incorporated in 1967 and is headquartered in Mumbai, India. Procter & Gamble Health Limited is a subsidiary of Procter & Gamble Overseas India BV.

www.pghealthindia.com

1,336

Full Time Employees

June 30

Fiscal Year Ends

Recent News: PGHL.NS

View More

Performance Overview: PGHL.NS

Trailing total returns as of 4/3/2025, which may include dividends or other distributions. Benchmark is S&P BSE SENSEX (^BSESN) .

YTD Return

PGHL.NS
2.74%
S&P BSE SENSEX (^BSESN)
2.36%

1-Year Return

PGHL.NS
14.29%
S&P BSE SENSEX (^BSESN)
3.27%

3-Year Return

PGHL.NS
36.09%
S&P BSE SENSEX (^BSESN)
28.71%

5-Year Return

PGHL.NS
50.89%
S&P BSE SENSEX (^BSESN)
176.52%

Compare To: PGHL.NS

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: PGHL.NS

View More

Valuation Measures

Annual
As of 4/2/2025
  • Market Cap

    87.30B

  • Enterprise Value

    84.46B

  • Trailing P/E

    36.88

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    7.67

  • Price/Book (mrq)

    14.29

  • Enterprise Value/Revenue

    7.42

  • Enterprise Value/EBITDA

    24.51

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    20.40%

  • Return on Assets (ttm)

    21.08%

  • Return on Equity (ttm)

    33.41%

  • Revenue (ttm)

    11.6B

  • Net Income Avi to Common (ttm)

    2.37B

  • Diluted EPS (ttm)

    142.45

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    2.73B

  • Total Debt/Equity (mrq)

    1.36%

  • Levered Free Cash Flow (ttm)

    2.16B

Research Analysis: PGHL.NS

View More

Company Insights: PGHL.NS

Research Reports: PGHL.NS

View More

People Also Watch